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Abstract
The synthesis and antiproliferative activity of a new series of rigid analogues of combretastatin A-4 are
described which contain the 1,4-diaryl-2-azetidinone (β-lactam) ring system in place of the usual
ethylene bridge present in the natural combretastatin stilbene products. These novel compounds are also
substituted at position 3 of the β-lactam ring with an aryl ring. A number of analogues showed potent
nanomolar activity in human MCF-7 and MDA-MB-231 breast cancer cell lines, displayed in vitro
inhibition of tubulin polymerization and did not cause significant cytotoxicity in normal murine breast
epithelial cells. 4-(4-Methoxyaryl)-substituted compound 32, 4-(3-hydroxy-4-methoxyaryl)-substituted
compounds 35 and 41 and the 3-(4-aminoaryl)-substituted compounds 46 and 47 displayed the most
potent anti-proliferative activity of the series. β-Lactam 41 in particular showed sub-nanomolar activity
in MCF-7 breast cancer cells (IC50 = 0.8nM) together with significant in vitro inhibition of tubulin
polymerization and has been selected for further biochemical assessment. These novel β-lactam
compounds are identified as potentially useful scaffolds for the further development of antitumour
agents which target tubulin.

Key words: Combretastatin A-4 analogues, β-lactam, azetidinone, cytotoxicity, tubulin, colchicine,
structure-activity.
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Abbreviations
CA-4

Combretastatin A-4

EI

Electron Impact

ER

Estrogen receptor

GTP

Guanidine triphosphate

HRMS

High Resolution Molecular Ion Determination

IC

Inhibitory concentration

MTD

Maximum tolerated dose

MTT

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NCI

National Cancer Institute

NMR

Nuclear Magnetic Resonance

PBS

Phosphate buffer saline

SAR

Structure-Activity Relationship

TBDMS

tert-Butyldimethylchlorosilane

THF

Tetrahydrofuran

TMCS

Trimethylchlorosilane

TMS

Tetramethylsilane
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Introduction
Microtubules are cytoskeletal structures which formed by self assembly of  and  tubulin heterodimers
and are involved in many cellular functions1. Their most important role is in the formation of the mitotic
spindle and they are essential to the mitotic division of cells. Tubulin is an  heterodimeric protein
which is the main constituent of microtubules. Tubulin is the target of numerous small molecule antiproliferative ligands that act by interfering with microtubule dynamics2. These ligands can be broadly
divided into two categories; those that inhibit the formation of the mitotic spindle such as colchicine (1,
figure 1)3, 4 and vinblastine5 and those that inhibit the disassembly of the mitotic spindle once it has
formed, such as paclitaxel6. The three characterised binding sites of tubulin are the taxane domain, the
vinca domain and the colchicine domain and many compounds interact with tubulin at these known
sites. Many tubulin binding compounds, such as paclitaxel and vinblastine are in clinical use for various
types of cancer.2 Antimitotic agents are one of the major classes of cytotoxic drug for cancer treatment
and microtubules are a significant target for many natural product anticancer agents such as
combretastatin A-4 (2a, figure 1)7 and podophyllotoxin (4, figure 1)2, 8.
The combretastatins are a group of diaryl stilbenes isolated from the stem wood of the South African
tree Combretum Caffrum9. 2a was found to have potent anticancer activity against a number of human
cancer cell lines including multi-drug resistant cancer cell lines and binds to the colchicine-binding site
of tubulin10. A water-soluble prodrug, combretastatin A-4-phosphate (2b, figure 1) is now in clinical
trials for thyroid cancer11-13 and in patients with advanced cancer14. 2b induces vascular shutdown
within tumours at doses less than one-tenth of the maximum tolerated dose and without detectable
morbidity, assuming a MTD of 1000mg/kg7. Hydrolysis in vivo by endogenous non-specific
phosphatases under physiological conditions affords 2a15, 16. The amino derivative of 2a (compound 3a)
is also in clinical trials as a water soluble amino acid prodrug (3b, figure 1)17. In contrast to colchicine,
the anti-vascular effects of 2a in vivo are apparent well below the maximum tolerated dose, offering a
wide therapeutic window. 2a as well as being a potent inhibitor of colchicine binding is also shown to
4

inhibit the growth and development of blood vessels, angiogenesis5, 18-21. The cis configuration only of
2a is biologically activity, with the trans form showing little or no activity22. The active cis double bond
in 2a is readily converted to the more stable trans isomer during storage or metabolism, resulting in a
dramatic decrease in antitumour activity23, 24.
Various structural modifications to 2a have been reported including variation of the A and B-rings
substituents25-27. Many modifications of the B-ring result in decreased bioactivity; however, substitution
of the 3’-OH with an amino group results in potent bioactivity and good water solubility 28. The 3,4,5trimethoxy substituted pattern in ring A, resembling the trimethoxyaryl ring of colchicine is optimal for
bioactivity of 2a24. Many conformationally restricted analogues of 2a are known. The majority of these
compounds replace the cis-double bond in 2a with a heterocyclic rigid ring scaffold structures which
prevents isomerisation of the cis-double bond. These analogues include the heteroarylcoumarin29,
aroylindole27,27 imidazole30, 1,3-dioxolane 31, pyrazole23, furazan (1,2,5-oxadiazole)25 and benzoxepin32
ring systems. Such non-isomerisable compounds inhibit cell growth of several human cancer cell lines
and many have been shown significant tubulin binding and depolymerising effects. We now describe
the synthesis and tubulin targeting activity of non-isomerisable β-lactam-containing analogues of 2a.
The anticancer activity of some β-lactam-containing compounds has been reported33, including the nonisomerisable combretastatin analogues containing OH and OMe substituents at C-334. We have recently
reported the potent antiproliferative activity of β-lactam-containing compounds which are unsubstituted
at C-3 or contain methyl substituent(s) at C-335. We have also reported antiproliferative and
antiestrogenic activity of compounds containing the β-lactam scaffold in MCF-7 cells36. In continuation
of our earlier work, a further panel of compounds containing the β-lactam ring were examined as
potential tubulin targeting agents. These novel compounds contain an aryl-type substituent at C-3, while
the rigid β-lactam ring scaffold structure allows a similar spatial arrangement between the two phenyl
rings as observed in the cis conformation of 2a.

5

Chemistry
The synthesis of the target β-lactams is illustrated in Schemes 2-4. The compounds which were initially
chosen for synthesis contained the 3,4,5-trimethoxyphenyl (Ring A) as the -lactam N-1 and 4methoxyphenyl as the -lactam C-4 substituents, which are present in 2a. β-Lactam synthesis was
achieved with a Staudinger cycloaddition reaction between a ketene (generated from an acid chloride)
and an imine under basic conditions33,

37

. The required imines 5a-f were obtained by condensation

reaction of the appropriately substituted benzaldehydes and anilines, (Scheme 1). In the case of 5e, the
phenolic group present on the starting 3-hydroxy-4-methoxybenzaldehyde was first protected as the tertbutyldimethylchlorosilane (TBDMS) ether38 which can be removed later under mild conditions with
tetrabutylammonium flouride which is suitable for the stability of the -lactam functional group39. Acid
chlorides 6a-6d were prepared by reaction of the appropriately substituted acetic acids with thionyl
chloride. For the preparation of the acid chloride 6c, (3-hydroxylphenyl)acetic acid was first treated with
benzyl bromide to afford (3-benzyloxyphenyl)acetic acid40. The acid chloride 6d is prepared from (4aminophenyl)acetic acid on first reaction with benzyl chloroformate to afford the (4benzyloxycarbonylaminophenyl)acetic acid41, which was then converted to the unstable acid chloride 6d
on reaction with thionyl chloride, (Scheme 2, step a). The chlorination reactions were monitored by IR
spectroscopy until acid chloride carbonyl absorption was observed (ν1790-1815cm-1).
The racemic -lactam products 7- 14 were obtained in low yields on treatment of the imines 5a-f at
reflux in dichloromethane with the appropriate acid chloride in the presence of triethylamine (Scheme 2,
Route I; one enantiomer only shown). -Lactam compounds 15-17 were prepared using a modified
procedure at room temperature as they were not successfully obtained by the usual conditions of the
Staudinger reaction (Scheme 2, Route II). Failure to form β-lactams with 4-nitrophenylacetyl chloride
under standard Staudinger conditions has previously been reported42. The stereochemistry of the lactam products obtained in Staudinger reactions depends on numerous factors, including the reaction
conditions, the order of addition of the reagents and the substituents present on both the imine and on
6

the acid chloride33, 43. In the present reactions, the trans products were isolated exclusively in all cases,
as evident from the 1H NMR spectrum of compound 7 where the H-3 and H-4 were identified at δ4.23
and δ4.79respectively as a pair of coupled doublets, J3,4 = 2.0Hz.
The β-lactams 18-31 were obtained directly from the appropriate phenylacetic acid using an acidactivating agent in a one-step reaction, (Scheme 2, Route III), which was the reaction of choice for the
majority of the products. Many acid-activating agents have been reported for this reaction e.g.
Mukaiyama’s reagent (2-chloro-N-methylpyridinium iodide), ethyl chloroformate, trifluoroacetic
anhydride, p-toluenesulfonyl chloride and various phosphorous derived reagents including triphosgene,
which was successfully used in the present study.44 Trans stereochemistry was also observed for these
products, e.g. for compound 18 where the H-3 and H-4 were identified at δ4.20 and δ4.89respectively
as a pair of coupled doublets, J3,4 = 2.5Hz. With selected phenylacetic acid derivatives, this reaction was
unsuccessful and the acids were converted to acid chlorides 6a – 6d. β-Lactams were then obtained by
the Staudinger route (Route I) as described above.
In some cases, a Reformatsky reaction was used for the synthesis of the required β-lactam compounds,
(Scheme 3)45, 46. We have recently reported the application of the Reformatsky reaction to obtain 1,3diaryl azetidinones which are unsubstituted at C-3 or contain methyl substituent(s) at C-335. We now
report the preparation of 1,3,4-triaryl azetidinones using a Reformatsky reaction which has been adapted
for microwave conditions. Previous investigations found TMCS to be superior for zinc activation 47 in
Reformatsky reactions than either iodine or zinc washed with 10% nitric acid. We examined the use of
zinc powder which was pre-activated with trimethylchlorosilane in microwave conditions in the
Reformatsky reactions, resulting in slightly increased yield of the desired β-lactam products 32-34 and a
significant reduction in the reaction time from 8 hours to 30 minutes, (Scheme 3). In the present
reactions, the trans products were isolated exclusively in all cases, as evident from the 1H NMR
spectrum of compound 32 where the H-3 and H-4 were identified at δ 4.29 and δ 4.87 ppm
3,4

= 2.5Hz. The trans configuration can be seen in the X7

ray crystal structure of β-lactam 32 in Figure 2. The enantiomeric composition of compound 32 was
clearly demonstrated on analysis by chiral HPLC, (rt 11.93 min and 12.53 min).
The phenolic products 35-38 were obtained on treatment of the silyl ethers 13, 29, 30 and 34
respectively with tetrabutylammonium fluoride at 0˚C (Scheme 4). Phenolic products 39-42 were
obtained by careful hydrogenolysis of the corresponding benzyl ethers 12, 28, 37 and 31 respectively
(Scheme 5). Reduction of the nitro group in compounds 15, 14 and 17 to the corresponding amines 43,
44 and 45 respectively was achieved by treatment with zinc dust and glacial acetic acid (Scheme 6).
Treatment of the carbamate protected compounds 38 and 16 with hydrogen and palladium afforded the
amines 46 and 47 respectively (Scheme 7).
To further investigate the contribution of the -lactam carbonyl group to the activity of this compound
class, a novel thione analogue 48 was prepared in good yield by reaction of the compound 32 with
Lawesson’s reagent (2,4-bis-(4-methoxyphenyl)-1,2,3,4-dithiaphosphetane-2,4-disulfide), (Scheme 8).
The characteristic C=S absorption band was observed at ν 1592.5 cm-1 for this product. A broad variety
of β-lactams have been subjected to reductive ring-opening with metal hydrides to yield the
corresponding γ-aminoalcohols.48 To investigate the contribution of the intact β-lactam ring structure to
the activity of this series of compounds, 35 was subjected to treatment with LiAlH4 to afford the
aminoalcohol product 49 which was isolated by an acid-base extraction to give the desired γaminoalcohol, (Scheme 9). Cleavage of the -lactam N1-C2 bond usually takes place with nucleophilic
reagents such as alkoxide ion.49-52 The ease of hydrolysis is apparently a function of increasing size and
number of substituents at the 3-position; with increased size and number hydrolysis becomes
increasingly difficult.53 A methoxide ring opening reaction was carried out on 35 with 4 equivalents of
sodium methoxide at room temperature over eight days, until reaction was complete on TLC. 1H NMR
analysis of the product 50 indicated formation of a diastereomeric product mixture, (Scheme 9).51, 52 For
methyl ester 50, the presence of two amino signals at δ 5.75 ppm and δ 6.10 ppm are indicative of two
isomers. There are also two signals for each of the α and β protons (formerly at positions 3 and 4 of the
8

azetidinone ring) between δ 3 ppm and δ 5 ppm. In the 13C NMR spectrum of 50, there are two carbonyl
signals at δ 171.55 ppm and δ 172.70 ppm.
The structures of the various β-lactams synthesized are illustrated in Tables 1, 2 and 3, together with
their routes of synthesis. Table 1 lists the initial β-lactams with the methoxy functionalities at different
positions of the β-lactam scaffold. The comprehensive series of β-lactams prepared with structural
modification of aryl ring at the C-3 position of the β-lactam heterocycle are listed in Table 2. Finally,
Table 3 shows further phenolic and amino modifications to the initial series of compounds with the aim
of improving activity. Compounds 32 and 35 were selected for chemical stability analysis and further
development based on the analysis of their drug-like (Lipinski) properties together with predictions of
permeability, metabolic stability, Pgp substrate status, blood-brain barrier partition, plasma protein
binding and human intestinal absorption properties. The stability of the target compounds 32 and 35 was
evaluated in phosphate buffer at pH values 4, 7.4 and 9, and the half-life was determined to be greater
than 24 hours for each compound at these pH values.
Antiproliferative activity
These analogues were first evaluated for their anti-proliferative activity in the MCF-7 (ER-positive)
human breast cancer cell line, and the most potent compounds were then screened against the MDAMB-231 cell line (ER-negative). The activities of the azetidin-2-ones are presented in Tables 4 and 5. In
addition, compounds 32 and 35 were evaluated in the NCI-60 cell line screen (Table 9, Supporting
information). Initially, the azetidin-2-ones prepared containing a 4-methoxy substituent on the C-4
phenyl ring were examined (compounds 7-12, 14, 15, 17-27, 32). From these early lead compounds, a
more extensive series of active derivatives were synthesized containing the 3-hydroxy-4-methoxy and 3amino-4-methoxy substitution pattern on the C-4 phenyl ring, (compounds 35, 36, 39-47). This latter
series of compounds was designed to contain similar structural features to 1, 2a and the CA-4 amino
analogue (3a).

9

The positions of the 3,4,5-trimethoxyphenyl and 4-methoxyphenyl ring substitution were initially
examined at different location on the azetidinone ring (compounds 7, 18, 32, and 33), Table 4. 2a was
used as the positive control. The optimal positioning was found to be in compound 32 (IC50 MCF-7 =
34nM), where the 3,4,5-trimethoxyphenyl ring is located at the N-1 position and the 4-methoxyphenyl
ring is at the C-4 position, as previously observed by Sun et al for other -lactam compounds34. Any
other arrangement of these two rings was significantly less active than 32 by a factor of over 1,000. The
effect of the introduction of substituents onto the C3-aryl ring of compound 32 was next investigated. In
the 3-arylsubstituted series (compounds 7 to 31), larger substituents such as 3,4,5-trimethoxyphenyl
(20), 4-trifluoromethylphenyl (27) and 4-benzyloxyphenyl (12) were not tolerated and lead to a
significant decrease in activity against MCF-7 cells. The most active analogues in this series were found
to be those with small, polar substituents including examples 24 (4-fluorophenyl), 39 (4hydroxyphenyl), 40 (3-hydroxyphenyl) and 43 (4-aminophenyl) with IC50 values in MCF-7 cells of
42nM, 59nM, 68nM and 50nM respectively.
The activity of the series was further optimized by modification of the C-4 aryl substituent of the
azetidinone ring to include either a hydroxy or an amino group as in compounds 35 – 38 and 41 – 47
(Schemes 4-7, Table 4). Analogues of the three most active compounds from Table 2 were synthesised
with both 4-(3-hydroxy-4-methoxyphenyl) and 4-(3-amino-4-methoxyphenyl) substitution (Table 3).
With one exception, the 3-hydroxy-4-methoxy substituted analogues were over 10-fold more active than
their corresponding 3-amino-4-methoxy derivatives (compare 41 to 42, for example, IC50 values of
0.8nM and 39.5nM respectively in MCF-7 cells). The exception was the fluorinated analogues, in which
the introduction of an amino substituent to the C-4 phenyl ring of 24 resulted in a slight increase in
potency (compound 45) when compared to the hydroxyl analogue 36, and both were less active than
compound 24 (IC50 values of 55nM, 66nM and 42nM respectively in MCF-7 cells). The activity of
nitro-substituted compound 17 is included for comparison (IC50 of 1.4μM), indicating the critical
importance of a polar H-bonding substituent on the C-3 phenyl ring. The phenolic hydroxyl group is the
optimal substituent at the 3-position of the 4-phenyl ring. The most potent compound in the series, 41,
10

displayed sub-nanomolar antiproliferative activity in the MCF-7 cell line with an IC50 of 0.8nM. Figure
3 shows a dose-response result for the antiproliferative effect of β-lactam compounds 32 and 41 in
MCF-7 cells. Compound 46, containing a 3-(4-aminophenyl) substituent also showed greater activity
than the lead compound 32, with an IC50 of 4nM in MCF-7 cell line.
The replacement of the -lactam carbonyl group with the thione in compound 48 resulted in a reduction
in the observed antiproliferative activity (IC50 = 0.72μM for MCF-7 cells and IC50 = 0.89μM for MDAMB 231 breast cancer cells). The β-lactam ring is strained and can undergo a number of ring-opening
reactions. In the present work, two ring-opened products were also synthesised and evaluated for
antiproliferative activity to assess the lactam scaffold dependence of biological activity. Alcohol 49 is
the result of treatment of 35 with lithium aluminium hydride while ester 50 is the product from the
nucleophilic ring-opening reaction of 35 with sodium methoxide. These compounds are more flexible
than the rigid β-lactam parent compound 35. They show over 2,000-fold decrease in antiproliferative
activity, indicating the critical importance of the rigid β-lactam scaffold and the relative orientations of
the two methoxy-containing aromatic rings for preservation of antiproliferative activity. The importance
of the relative orientations of the two aromatic rings has also been noted previously for CA-422.
The more potent compounds in the MCF-7 cell line were next examined in an ER-negative MDA-MB231 cell line and the results are displayed in Table 5. Compound 35 was found to be the most effective
of the series with IC50 value of 28nM; compounds 32 and 45 are also seen to be effective, with IC50
values of 78nM and 80nM respectively. Compound 41 was also evaluated in the leukaemia cell lines
HL-60 and K562 and was found to be extremely potent with IC50 values of 0.34nM and 0.89nM
respectively, which compared favourably with the control 2a [IC50 values of 1.99nM(HL-60 ) and
3.68nM(K562)].
Based on their potency, compounds 9 and 35 were evaluated in the National Cancer Institute
(NCI)/Division of Cancer Treatment and Diagnosis (DCTD)/Developmental Therapeutics Program
(DTP)54, in which the activity of each compound was determined using approximately 60 different
cancer cell lines of diverse tumour origins. These studies were performed at the NCI as part of their
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drug-screening program. Compounds 9 and 35 were tested for inhibition of growth (GI50) and for
cytotoxicity (LC50) in the NCI panel of 56 cell lines and showed broad-spectrum antiproliferative
activity against tumour cell lines derived from leukaemia, breast cancer, non-small cell lung cancer,
colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer and prostate cancer, (see Table 9,
Supporting Information). β-Lactam 9 showed submicromolar GI50 values in all but 5 cell lines (the GI50
value is the concentration of drug required for 50% inhibition of cellular growth). The mean GI50 value
for compound 9 across all cell lines is 0.21μM [log GI50=(-6.67M)]. For compound 35, the GI50 values
obtained were below 10nM for 38 of the cell lines investigated, including breast cancers MCF-7, MDAMB-231 and the Adriamycin resistant NCI/ADR-RES cell line, with the mean GI50 value across all cell
lines = 23.99nM, [log GI50=(-7.62M)]. LC50 values are a measure of the cytotoxicity of these
compounds and were greater than 100μM for compound 9 in all but three cell lines and greater than
100μM for compound 35 in all but ten cell lines (Table 9, Supporting Information). These results
confirm the requirement for the 3-hydroxy-4-methoxy substitution pattern on Ring B for optimum
antiproliferative activity in these analogues.
COMPARE analysis of β-lactams 9 and 35
Matrix COMPARE analysis55,

56

(measuring the correlation between two compounds with respect to

their differential antiproliferative activity) demonstrated good correlation between 35 and 2a (r=0.62),
and other tubulin binding drugs vincristine, vinblastine, paclitaxel, maytansine and rhizoxin (Table 10,
Supporting Information). However, this algorithm does not distinguish between different tubulin-based
mechanisms of action.57 In vitro tubulin-binding studies confirmed that 35 is acting as a tubulin-binding
agent. The antiproliferative activity observed for these compounds indicated that there is a significant
therapeutic window between the concentration required for cancer cell growth inhibition and the
concentration that is toxic to cells.
Evaluation of toxicity in normal murine mammary epithelial cells
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Two of the most potent β-lactam compounds from antiproliferative studies in the MCF-7 cell line, 35
and 41, were evaluated further for cytoxicity in murine mammary epithelial cells. 2a was used as the
positive control. Mouse mammary epithelial cells were harvested from mid- to late- pregnant CD-1
mice and cultured as described previously58,59. Two different cell concentrations were used in the
toxicity assay; 25,000 cells/ml and 50,000 cells/ml. The results are presented in Figure 4 and in the
Supplementary information (figures 10, 11, 12). The IC50 value is greater than 10mM for the three
compounds evaluated. This is further evidence that these β-lactam compounds are minimally toxic to
non-proliferating cells.

Tubulin binding studies
The effects of representative β-lactam CA-4 analogues on the assembly of purified bovine tubulin were
evaluated. Compounds 32, 35 and 41 which demonstrated potent antiproliferative effects in vitro were
assessed. The ability of 2a to effectively inhibit the assembly of tubulin was assessed as a positive
control. Tubulin polymerisation was determined by measuring the increase in absorbance over time at
340nm. The Vmax value offers the most sensitive indicator of tubulin/ligand interactions and hence Vmax
values were calculated for each test compound. Fold changes in Vmax values for polymerisation curves
of each test compound with reference to ethanol control were calculated and are detailed in Table 6. As
anticipated, the active β-lactam CA-4 analogues 32, 35 and 41 inhibited the polymerisation of tubulin
(Table 9, Supporting information). In more detail, the active β-lactams when evaluated at 10 µM
concentration, reduced the Vmax value for the rate of tubulin polymerisation from 6-fold for 2a to 11.7fold for compound 41, and to 8.3-fold for compound 35, while compound 32 showed a 6-fold reduction
in the value for Vmax. This value is comparable if not superior to the rate of inhibition of tubulin
assembly (6-fold) observed with 2a. An IC50 value of 3.65M was calculated for compound 41 for the
reduction in Vmax, while IC50 value of 4.89M was obtained for the effect in overall polymer mass
(calculated from area under the polymerization curve). Inhibition of tubulin polymerisation for
13

compound 41 is illustrated in Figure 5. The tubulin binding studies clearly demonstrated that tubulin is
the target of these new compounds; however, the specific binding site on tubulin was not investigated
e.g. by use of a radiolabelled colchicine displacement assay. Based on the very close 3D structural
similarity between the ligands 1, 2a and the beta-lactam analogues reported in this study (figures 6b and
7d), we propose that the binding site for these compounds is most likely to be the colchicine site, since it
has been demonstrated that 2a and many reported examples of the structurally related conformationally
constrained 2a analogues bind at the colchicine site27, 60, 61.
Structural and Molecular modeling studies of selected azetidinones
The molecular structure of a representative example of the active series, compound 32, was determined
by single-crystal X-Ray crystallography. The ORTEP diagram is presented in Figure 2, where the trans
configuration at positions 3 and 4 of the β-lactam ring clearly seen (note that in the X-ray numbering
scheme in Figure 2, the carbon at the 3-position of the beta-lactam ring is denoted as C2 and the carbon
the 4-position of the beta-lactam ring is denoted as C3). The structure revealed a conformation for the
azetidinone 32 in which the two aromatic rings located at N-1 and C-4 are not coplanar. The rigid
azetidinone ring provides a scaffold which can accommodate the steric and geometric requirements of
the aromatic pharmacophores for tubulin binding. Ligands that bind at the colchicine-binding site of
tubulin have the common feature of a trimethoxy-aromatic ring, noted for such ligands as 1, 2a and 4.
The azetidinone 32 is structurally similar to 1 and 2a, with the common structural features of a
trimethoxyphenyl ring and a second aromatic ring substituted with methoxy groups in a non co-planar
diaryl system, with the observed tortional angle for Ring A–Ring B of 46.9o compared to 55oand 53o for
the corresponding rings in 2a62 and 163 respectively. These structural similarities support the observed
antiproliferative and tubulin polymerization inhibitory activity for these compounds as tubulin-targeting
agents. The X-ray crystal structures of 2a62 and 2b22 suggest that the conformation of this stilbene is not
planar. These crystal structures reveal that the planes of the two phenyl rings are inclined to each other,
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suggesting a low-energy conformation that may be the one involved in binding at the tubulin receptor
site22.
To rationalize the potential binding modes of these β-lactam compounds in tubulin, docking studies
were carried out with two of the most potent compounds in the 3-aryl β-lactam series, 32 and 41. Using
the reported X-ray structure of tubulin co-crystallised with a colchicine derivative, N-deacetyl-N-(2mercaptoacetyl)-colchicine (DAMA-colchicine, PDB entry – 1SA0), possible binding orientations for
32 and 41 were probed with the docking program FREDv2.2.3 (Openeye Scientific Software)64. Due to
the structural similarity between the β-lactams and colchicine site ligands such as 2a, it was proposed
that 32 and 41 bind to tubulin at the colchicine-binding site. The colchicine-binding site in tubulin is
mainly buried in the β-subunit, whilst maintaining few interactions with the α-subunit; there is one such
site on each tubulin heterodimer. The H7 and H8 α-helices, the T7 loop and the S8 and S9 β-strands
contribute to the binding site and interact with the ligand. Two important residues for binding of
colchicine-type ligands to tubulin have been identified as Val β318 and Cys β24163. Val β318 tubulin
variants have reduced sensitivity to 1 and colchicine substituted with more reactive groups instead of the
methoxys can be crosslinked with Cys β24163.
Molecular modeling studies were carried out with the β-lactam compounds synthesised and evaluated
to determine if these interactions were predicted to be present. Figure 6a illustrates β-lactam 32 docked
in the colchicine-binding site of tubulin, while Figures 7a and 7b show similar graphics with β-lactam
41 docked. β-Lactam 41 was the most active compound in anti-proliferative assays and also in the
tubulin polymerization inhibition assay. The two important residues for binding in the colchicinebinding site of tubulin are identified as Val β318 and Cys β241. Figures 6a, 7a and 7b show the
trimethoxy ring of both 32 and 41 is well positioned in proximity to the Cys241 residue (residue
numbers are those used by Ravelli et al63), and the compounds adopt a very similar orientation to that of
the trimethoxy ring of DAMA-colchicine in the co-crystallized structure. In addition, for compound 41,
Thr 179 is seen to establish a strong H-bond to the 3-OH substituent of ring B (Figure 7a, 7b). This
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residue has previously been identified as interacting with a number of colchicine site ligands 32,

65, 66

.

This interaction may also explain the binding of the related compound in the series with an OH
substituent in similar position (e.g. compounds 35, 36, 46), and also the related analogues with NH2
substituent at C-3 of the aryl B-Ring. Activity is optimized by additional substituents on the C-3 aryl
such as 4-F, 4-NH2, 4-OH, 3-OH (compounds 24, 39, 40, 43) which preserve the key interactions with
active residues for Ring A and Ring B. The H-bonding interaction between the 4-hydroxyaryl group at
the 3-position of β-lactam 41 and the Lys 254 residue (Figure 7a, 7b), in addition to hydrophobic
contacts with the 3-phenyl ring (not shown for clarity) could contribute to the observed higher
antiproliferative activity observed for this analogue. The hydrophobic interactions are illustrated in
Figure 7c and include interactions of the 3-phenyl ring with Leu248, Ala250 and Leu255. Activity is
significantly reduced for β-lactam analogues of 32 that have multiple methoxy substitutions on the C-3
aryl ring as in compound 20, or increased steric hindrance with the benzyloxy ether (compound 28).
Several other hydrophobic contacts are predicted to stabilize the binding of 32 and 41 to tubulin.
Figures 6c and 7c depict the predicted binding interactions of docked β-lactams 32 and 41 in 2D
format67. From these results it can be seen that the important interactions discussed above are predicted
to be present for these compounds. The docked pose of 32 (colored by atom) overlaid with colchicine
(yellow) in the tubulin binding site is illustrated in Figure 6b. It can be seen that the methoxy substituent
of Ring B is in close proximity in the binding site to the corresponding methoxy group on Ring C of
colchicine. A similar binding orientation is observed for colchicine and 41 (Figure 7d). These binding
parallels may rationalise the potency observed for 32 and 41 in their inhibition of tubulin
polymerisation.
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Conclusion
We have synthesized a comprehensive series of -lactam compounds which show potent
antiproliferative activity in a range of tumour cell lines, notably in human breast cancer MCF-7 and
MDA-MB-231 cell lines. The most potent compound in the series 41 displayed sub-nanomolar activity
in the MCF-7 cell line with an IC50 of 0.8nM. Compound 46 containing a 3-(4-aminophenyl) substituent
also showed greater activity than the lead compound 32, with an IC50 of 4nM in MCF-7 cell line, with
the 3-phenylsubstituted -lactam 32 having an IC50 of 34nM. The compounds did not cause significant
cytotoxicity in normal murine breast epithelial cells. Compounds 32, 35 and 41 were shown to inhibit
the polymerization of tubulin with improved efficacy when compared with 2a.
X-ray crystal structure of 32 revealed that the compound provides a scaffold structure with a similar
spatial arrangement between the two phenyl rings as observed in cis configuration of 2a. Preliminary
modeling studies indicate a possible binding mode for these potent inhibitors of tubulin polymerization.
These conformationally restricted -lactam structures are not easily isomerised, unlike the cis-stilbene
2a, and are identified as promising lead compounds in the development of new anticancer agents.
Further studies are in progress to further rationalize SAR for this series of azetidinones and to determine
the antiangiogenic effects of these compounds.
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Experimental section
All reagents were commercially available and were used without further purification unless otherwise
indicated. Tetrahydrofuran (THF) was distilled immediately prior to use from Na/Benzophenone under
a slight positive pressure of nitrogen, toluene was dried by distillation from sodium and stored on
activated molecular sieves (4Å) and dichloromethane was dried by distillation from calcium hydride
prior to use. IR spectra were recorded as thin films on NaCl plates or as KBr discs on a Perkin-Elmer
Paragon 100 FT-IR spectrometer. 1H and 13C NMR spectra were obtained on a Bruker Avance DPX 400
instrument at 20oC, 400.13MHz for 1H spectra, 100.61MHz for 13C spectra, in either CDCl3, CD3COCD3
or CD3OD (internal standard tetramethylsilane). Low resolution mass spectra were run on a HewlettPackard 5973 MSD GC–MS system in an electron impact mode, while high resolution accurate mass
determinations for all final target compounds were obtained on a Micromass Time of Flight mass
spectrometer (TOF) equipped with electrospray ionization (ES) interface operated in the positive ion
mode at the High Resolution Mass Spectrometry Laboratory by Dr. Martin Feeney in the School of
Chemistry, Trinity College Dublin. Thin layer chromatography was performed using Merck Silica gel
60 TLC aluminium sheets with fluorescent indicator visualizing with UV light at 254nm. Flash
chromatography was carried out using standard silica gel 60 (230-400 mesh) obtained from Merck. All
products isolated were homogenous on TLC. The purity of the tested compounds was determined by
HPLC or combustion analysis and unless otherwise stated, the purity level was >95%. Elemental
analyses were performed on an Exetor Analytical CE4400 CHN analyser in the microanalysis
laboratory, Department of Chemistry, University College Dublin. Analytical high-performance liquid
chromatography (HPLC) was performed using a Waters 2487 Dual Wavelength Absorbance detector, a
Waters 1525 binary HPLC pump and a Waters 717plus Autosampler. The column used was a Varian
Pursuit XRs C18 reverse phase 150 x 4.6mm chromatography column. Samples were detected using a
wavelength of 254 nm. All samples were analyzed using acetonitrile (70%): water (30%) over 10 min
and a flow rate of 1 mL/min. Chiral liquid chromatography was carried out on selected compounds
using a Chiral-AGPTM 150x4.0mm column supplied by ChromTech Ltd. (now supplied by Chiral
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Technologies Europe) with a Chiral- AGPTM guard column. The HPLC system consisted of the
following components: a Waters 1525 binary HPLC pump, a Waters 2487 Dual Wavelength
Absorbance Detector, a Waters In-Line Degasser AF and a Waters 717 plus Autosampler. Gradient
elution was used beginning with 10% of organic phase and finishing with 90% of organic phase over a
period of 20 minutes. The organic mobile phase was 2-propanol and the aqueous phase was a sodium
phosphate buffer. The sodium phosphate buffer, consisting of 10mM sodium dihydrogen
orthophosphate dihydrate (NaH2PO4) in HPLC-grade water, was made up to pH 7.0 using sodium
hydroxide. The flow rate was 0.5ml/minute and detection was carried out at 225 nm. Details of the
synthesis of intermediate compounds and characterizations of target β-lactams are contained in the
supplementary information.
General method for imine preparation
The appropriate amine (10 mmol) was refluxed with of the appropriate aldehyde (10 mmol), in
ethanol (50 mL) for 3 hours. The reaction mixture was reduced in vacuo and the resulting solution was
allowed to stand until solid product crystallised from solution. The resulting imine was recrystallised
from ethanol.
[3-(tert-Butyldimethylsilanyloxy)-4-methoxybenzylidene]-(3,4,5-trimethoxyphenyl)amine

(5e)

was prepared by reacting 3-(tert-butyldimethylsilanyloxy)-4-methoxybenzaldehyde with 3,4,5trimethoxybenzenamine following the general method above. The product was obtained as a yellow
solid. Yield 64.3%, M.p.105°C. IR (KBr) υ 1619.8 cm-1, 1579.73 cm-1 (-C=N-); 1H NMR (400 MHz,
CDCl3) δ 0.20 (s, 6H, 2xCH3), 1.03 (s, 9H, C(CH3) 3), 3.87 – 3.91 (m, 12H, 4xOCH3), 6.48 (s, 2H,
ArH), 6.93 (d, 2H, J=8.04 Hz, ArH), 7.43 – 7.47 (m, 1H, ArH), 8.35 (s, 1H, CH=N);
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C NMR (100

MHz, CDCl3) δ –5.04(CH3-Si-CH3), 18.03(CH3-C-CH3), 25.27(C(CH3)3), 54.98(- OCH3), 55.63(OCH3), 97.62, 110.94, 119.71, 123.48, 128.95, 135.53, 144.87, 147.94, 153.05, 153.59 (ArC), 158.84(C=N-). Elemental analysis: Found: C, 63.99; H, 7.65; N, 3.21; C23H33NO5Si requires C, 64.01; H, 7.71;
N, 3.25%.
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General method for β-lactam synthesis I: Staudinger reaction (compounds 7 – 14): The
appropriate imine (5 mmol) and triethylamine (15 mmol) were added to dry CH2Cl2 (50 mL) and the
mixture was brought to reflux at 60°C. The appropriate acid chloride (7.5 mmol) was then added
dropwise to the mixture via a septum. The reaction mixture was then refluxed for 3 h, then cooled and
washed firstly with distilled water (2x50 mL) and then with saturated aqueous sodium bicarbonate
solution (50 mL). The organic layer was dried by filtration through anhydrous sodium sulfate. The
organic layer containing the product was collected and reduced in vacuo. To afford the crude product
which was purified by flash column chromatography over silica gel (eluent: hexane:ethyl acetate
gradient).
General method for β-lactam synthesis II: Staudinger reaction modified (compounds 15 – 17): A
solution of the appropriate imine (10 mmol) and acid chloride (10 mmol) in CH2Cl2 (50 mL) under
nitrogen was stirred for 2 hours. Triethylamine (10 mmol) was added dropwise and the mixture was left
to stir overnight. The mixture was washed firstly with distilled water (2x50 mL) and then with saturated
aqueous sodium bicarbonate solution (50 mL). The organic layer was dried by filtration through
anhydrous sodium sulfate. The organic layer containing the product was collected and reduced in vacuo
to afford the crude product which was purified by flash column chromatography over silica gel (eluent:
hexane:ethyl acetate gradient 10:1 to 2:1).
General method for β-lactam formation III: Acid activation with triphosgene (compounds 18 –
31): Mixture of the appropriate acetic acid (15 mmol) and triphosgene [bis(trichloromethyl) carbonate]
(5 mmol) in dry CH2Cl2 (50 mL) was heated at refluxed for 30 minutes. A solution of the appropriately
substituted imine (10 mmol) in dry CH2Cl2 (10 mL) was added dropwise to the refluxing solution
followed by triethylamine (30 mmol). The reaction mixture was heated at reflux for 5 hours and stirred
at room temperature overnight. The mixture was washed firstly with distilled water (2x50 mL) and then
with saturated aqueous sodium bicarbonate solution (50 mL). The organic layer was dried over
anhydrous sodium sulphate to afford the crude product, which was purified by flash column
chromatography over silica gel (eluent: hexane : ethyl acetate gradient).
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3-(4-(Benzyloxy)phenyl)-4-(3-((tert-butyldimethylsilyl)oxy)-4-methoxyphenyl)-1-(3,4,5trimethoxyphenyl)azetidin-2-one 29 was obtained from (4-benzyloxyphenyl)acetic acid and imine 5e
following general method III as a brown oil, yield 6.8% and was deprotected immediately without
further purification to afford 37 (see below).
Benzyl(4-(2-(3-((tert-butyldimethylsilyl)oxy)-4-methoxyphenyl)-4-oxo-1-(3,4,5trimethoxyphenyl)azetidin-3-yl)phenyl)

carbamate

30

was

obtained

from

(4-

benzyloxycarbonylaminophenyl)acetic acid and imine 5e following general method III as an oil, yield
10.6% and was deprotected immediately to afford 38 without further purification.
General method for β-lactam preparation IV: Reformatsky reaction using microwave
(compounds 32 – 34): Zinc powder (0.927g, 15 mmol) was activated using trimethylchlorosilane (0.65
mL, 5 mmol) in anhydrous benzene (5 mL) by heating for 15 minutes at 40°C and subsequently for 2
minutes at 100°C in a microwave. After cooling, the appropriately substituted imine (10 mmol) and
substituted ethylbromoacetate (12 mmol) were added to the reaction vessel and the mixture was placed
in the microwave for 30 minutes at 100°C. The reaction mixture was filtered through Celite to remove
the zinc catalyst and then diluted with dichloromethane. This solution was washed with saturated
ammonium chloride solution (20 mL) and 25% ammonium hydroxide (20 mL), and then with dilute
HCl (40 mL), followed by water (40 mL). The organic phase was dried over anhydrous sodium sulfate
and the solvent was removed in vacuo to afford the crude product which was purified by flash column
chromatography over silica gel (eluent: hexane, ethyl acetate gradient) to afford the required -lactam
product
4-(4-Methoxyphenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 32 was obtained from
ethyl 2-bromo-2-phenylacetate and imine 5a following general method IV as a white crystalline solid,
yield 6.8%; m.p. 108ºC; IR (NaCl) υ: 1753.3 cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.72
(s, 6H, 2x-OCH3), 3.77 (s, 3H, -OCH3), 3.83 (s, 3H, -OCH3), 4.29 (d, 1H, J=2.5 Hz, H-3), 4.87 (d, 1H,
J=2.5 Hz, H-4), 6.60 (s, 2H, ArH), 6.95 (d, 2H, J=8.5 Hz, ArH), 7.32 – 7.40 (m, 7H, ArH);
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C NMR

(100 MHz, CDCl3) δ 54.92(-OCH3), 55.57(-OCH3), 60.52(-OCH3), 63.40(C-3), 64.59(C-4), 94.38,
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114.24, 126.89, 127.00, 127.45, 128.59, 128.85, 133.28, 134.00, 134.33, 153.05, 159.49(ArC),
165.21(C=O); HRMS: Calculated for C25H25NO5Na: 442.1630; Found: 442.1631 (M++Na).
4-(3-((tert-butyldimethylsilyl)oxy)-4-methoxyphenyl)-3-phenyl-1-(3,4,5trimethoxyphenyl)azetidin-2-one 34 was obtained from ethyl 2-bromo-2-phenylacetate and imine 5e
following general method IV as a yellow oil, yield 70%, and was immediately deprotected to form 35
without further purification.
Desilylation of β-lactams (General method V) (compounds 35 – 38): To a solution of the
appropriately protected phenol (10 mmol) in THF (50 mL) was added 1M tetrabutylammonium fluoride
(1.5 equivalents). The solution was stirred in an ice-bath for 15 minutes. The reaction mixture was
diluted with EtOAc (100 mL) and quenched with HCl (10%, 100mL). The layers were separated and the
aqueous layer was extracted with EtOAc (2 x 50 mL). The organic layer was then washed with water
(100 mL) and brine (100 mL), followed by drying over anhydrous sodium sulphate. The solvent was
removed by evaporation under reduced pressure and the crude product was purified by flash column
chromatography over silica gel (eluent: hexane and ethyl acetate gradient) to afford the required phenol
product.
4-(3-Hydroxy-4-methoxyphenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one

35

was

obtained from azetidinone 34 following general method V as a white solid, yield 97.3%, m.p. 110ºC; IR
(KBr) υ: 1718.2 cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.73 (s, 6H, 2x-OCH3), 3.78 (s,
3H, OCH3), 3.91 (s, 3H, OCH3), 4.27 (d, 1H, J=2.5 Hz, H-3), 4.81 (d, 1H, J=2.5 Hz, H-4), 5.75 (s, 1H,
OH), 6.63 (s, 2H, ArH), 6.86 – 6.93 (m, 2H, ArH), 7.00 (d, 1H, J=2.0 Hz, ArH), 7.31 – 7.39 (m, 5H,
ArH); 13C NMR (100 MHz, CDCl3) δ 55.58(OCH3), 55.60(OCH3), 60.51(OCH3), 63.36(H-3), 64.49(H4), 94.42, 110.59, 111.56, 117.40, 126.97, 127.43, 128.57, 130.10, 133.27, 134.02, 134.31, 145.91,
146.43, 153.05(ArC), 165.14(C=O); HRMS: Calculated for C25H25NO6Na:458.1580; Found: 458.1575
(M++Na).
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3-(4-(Benzyloxy)phenyl)-4-(3-hydroxy-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2one 37 was obtained from azetidinone 29 following general method V as a brown oil, yield 96.8%,
which was further deprotected to form 41 without purification.
{4-[2-(3-Hydroxy-4-methoxyphenyl)-4-oxo-1-(3,4,5-trimethoxyphenyl)-azetidin-3-yl]phenyl}
carbamic acid benzyl ester 38 was obtained from carbamate 30 following general method V, yield
33.7% , and was further deprotected to 46 without purification.
Debenzylation of β-lactams (General method VI) (compounds 39 – 42): The appropriate benzyl
ether compound (2 mmol) was dissolved in ethanol: ethyl acetate (50mL; 1:1 mixture) and
hydrogenated over palladium on carbon (1.2g, 10 %) at atmospheric pressure for 2 h. The catalyst was
filtered, the solvent was removed under vacuum and the product was purified by flash column
chromatography over silica gel (eluent: hexane: ethyl acetate gradient) to afford the phenolic product.
4-(3-Hydroxy-4-methoxyphenyl)-3-(4-hydroxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one
41 was obtained from azetidinone 37 following general method VI as a white powder, yield 2.9%, m.p.
152ºC; IR (NaCl film) υ: 1720.6 cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.65 (s, 3H, OCH3), 3.70 (s, 6H, 2x-OCH3), 3.86 (s, 3H, -OCH3), 4.26 (d, 1H, J=2.4 Hz, H-3), 4.98 (d, 1H, J=2.4 Hz,
H-4), 6.71 (s, 2H, ArH), 6.87 (d, 2H, J=8.8 Hz, ArH), 7.00 (s, 3H, ArH), 7.22 (d, 2H, J=8.8 Hz, ArH);
C NMR (100 MHz, CDCl3) δ 54.93(-OCH3), 59.23(-OCH3), 63.05(C-3), 63.76(C-4), 94.66, 111.31,
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112.22, 115.13, 117.48, 125.72, 128.25, 130.39, 133.49, 134.12, 146.70, 147.32, 153.25, 156.50(ArC),
165.27(C=O); HRMS: Calculated for C25H25NO7Na: 474.1529; Found 474.1548; (M++Na).
General method for reduction of nitro-substituted azetidinones (General method VII)
(compounds 43 – 45): To the appropriate nitro substituted β-lactam (10 mmol), dissolved in the
minimum amount of glacial AcOH (2-3 mL) was added metallic zinc dust (10 equiv). The mixture was
stirred for 6 days at room temperature under nitrogen. The residue was filtered through Celite and was
extracted with dichloromethane. The solvent was evaporated and the residue purified by flash column
chromatography over silica gel (eluent: hexane and ethyl acetate gradient) to afford the required amine
product.
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Deprotection of the Cbz protected azetidinones (General method VIII) (compounds 46 and 47):
The Cbz-protected compound (2 mmol) was dissolved in ethanol: ethyl acetate (50mL; 1:1 mixture) and
hydrogenated over palladium on carbon (1.2g, 10 %) for 2 hours. The catalyst was filtered, the solvent
was removed under vacuum and the product was purified by flash column chromatography over silica
gel (eluent: hexane : ethyl acetate gradient) to afford the amine product.
3-(4-Aminophenyl)-4-(3-hydroxy-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one
46 was obtained from carbamate 38 following general method VIII, as an orange oil, yield 39.4%; IR:
(NaCl film) υ: 1737.4 cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.75 (s, 6H, 2x-OCH3),
3.80 (s, 3H, -OCH3), 3.93 (s, 3H, -OCH3), 4.18 (d, 1H, J=2.5 Hz, H-3), 4.74 (d, 1H, J=2.5 Hz, H-4),
6.63 (s, 2H, ArH), 6.70 (d, 2H, J=8.3 Hz, ArH), 6.89 (m, 2H, ArH), 6.99 (s, 1H, ArH), 7.11 (d, 2H,
J=8.3 Hz, ArH);

C NMR (100 MHz, CDCl3) δ 55.56 (-OCH3), 55.59 (-OCH3), 60.51 (-OCH3),
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63.85(C-3), 64.19(C-4), 94.39, 110.54, 111.53, 115.15, 117.33, 124.24, 128.03, 130.32, 133.39, 145.39,
145.8, 146.32, 153.02(ArC), 165.60 (-C=O); HRMS: Calculated for C25H27N2O6: 451.1869; Found:
451.1859 (M+).
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Antiproliferative MTT assay: All assays were performed in triplicate for the determination of mean
values reported. Compounds were assayed as the free bases isolated from reaction. The human breast
tumour cell line MCF-7 was cultured in Eagles minimum essential medium in a 95%O2/5% CO2
atmosphere with 10% fetal bovine serum, 2mM L-glutamine and 100 µg/mL penicillin/streptomycin.
The medium was supplemented with 1% non-essential amino acids. MDA-MB-231 cells were
maintained in Dulbecco’s Modified Eagle’s medium (DMEM), supplemented with 10% (v/v) Fetal
bovine serum, 2mM L-glutamine and 100 µg/mL penicillin/streptomycin (complete medium). Cells
were trypsinised and seeded at a density of 2.5 x 104 cells/mL in a 96-well plate and incubated at 37oC,
95%O2/5% CO2 atmosphere for 24 h. After this time they were treated with 2 µL volumes of test
compound which had been pre-prepared as stock solutions in ethanol to furnish the concentration range
of study, 1 nM–100 µM, and re-incubated for a further 72 h. Control wells contained the equivalent
volume of the vehicle ethanol (1% v/v). The culture medium was then removed and the cells washed
with 100 µL phosphate buffered saline (PBS) and 50 µL MTT added, to reach a final concentration of 1
mg/mL MTT added. Cells were incubated for 2 h in darkness at 37oC. At this point solubilization was
begun through the addition of 200 µL DMSO and the cells maintained at room temperature in darkness
for 20 min to ensure thorough colour diffusion before reading the absorbance. The absorbance value of
control cells (no added compound) was set to 100 % cell viability and from this graphs of absorbance
versus cell density per well were prepared to assess cell viability using GraphPad Prism software48.
Cytotoxicity assay: Mammary glands from 14-18 day pregnant CD-1 mice were used as source and
primary mammary epithelial cell cultures were prepared from these. 1st to 3rd thoracic glands were
exposed by pulling the skin back from the rib cage to the forelimb and extracted in a similar way to the
inguinal glands. Mid-pregnant glands are large, soft and are pink in colour. Mammary glands that were
spongy and pale in colour were not used as these glands had matured and were producing milk. The
harvested glands were then subjected to mechanical and enzymatic digestion to release immature
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alveolar structures and isolate mammary epithelial cells. The dissected glands were weighed and fresh
collagenase digestion mixture prepared. It contained 480mg of F10 powdered medium (Sigma), 70mg
of trypsin (GibcoBrl, Life Technologies), 150mg collagenase A (GibcoBrl, Life Technologies) and
2.5ml of foetal calf serum (GibcoBrl, Life Technologies) in a final volume of 50ml (with sterile
water). The collagenase digestion mixture was subsequently adjusted to pH 7.4, filtered through a
0.2M sterile filter and stored at 4C until required. The dissected glands were minced criss-cross using
two sterile scalpel blades. The minced glands were placed in an autoclaved, sterile 250ml glass conical
flask with the collagenase digestion mixture (~4ml of digestion mixture per gram of tissue) and digested
for 90 minutes on a shaking table, 250rpm at 37C. After this step, a stringent washing/centrifugation
protocol was used to isolate epithelial cells from fibroblasts. Selective centrifugation was carried out as
follows: the digested cell suspension was removed to a 50ml tube and centrifuged for 30 seconds at
100rpm. The supernatant was transferred to a fresh tube and centrifuged at 800rpm for 3 minutes. The
pellet was then subjected to a DNase treatment in order to achieve separation of single epithelial cells
rather than cell clumps. The DNase mixture contained 480mg of F10 powdered medium (Sigma), 250l
of 10mg/ml DNase (Roche Diagnostics) and 250l of 1M MgCl2 brought up to a final volume of 50ml
(with water) and passed through a 0.2M sterile filter. The pellet was resuspended in the DNase mixture
and incubated at 37C for 30 minutes, on a shaking table at 150rpm. The cell suspension was then
transferred to a fresh 50ml tube and centrifuged at 800rpm for 3 minutes. The supernatant was
discarded. The pellet was resuspended in 30-50ml of Ham's F-12 medium (with gentamycin,
Biowhittaker), depending on the size of the pellet. Finally, the cell suspension was added to F-12
medium containing gentamycin (50g/ml) with the following hormones; hydrocortisone (H) 1g/ml
(Sigma, stock solution: 1mg/ml in 100% ethanol), insulin (I) 5g/ml (Sigma, stock solution: 5mg/ml in
5mM HCl) and epidermal growth factor (EGF) 5ng/ml (Promega, stock solution: 5g/ml in F-12
medium). The isolated mammary epithelial cells were seeded at two concentrations (25,000 cells/ml and
50,000 cells/ml). Initially a third concentration of 100,000 cells/ml was also used, but this proved to be
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too high to give meaningful results. After 24 hours, they were treated with 2 µL volumes of test
compound which had been pre-prepared as stock solutions in ethanol to furnish the concentration range
of study, 1 nM–100 µM, and re-incubated for a further 72 h. Control wells contained the equivalent
volume of the vehicle ethanol (1% v/v). The cytotoxicity was assessed using alamar blue dye.
Tubulin polymerization:

Tubulin polymerisation was carried out using a kit supplied by

Cytoskeleton. It is based on the principal that light is scattered by microtubules to an extent that is
proportional to the concentration of the microtubule polymer. Compounds that interact with tubulin will
alter the polymerisation of tubulin, and this can be detected using a spectrophotometer. The absorbance
at 340nm at 37°C is monitored. The experimental procedure of the assay was performed as described in
version 8.2 of the tubulin polymerisation assay kit manual68.
Stability study for compounds 32 and 35: Analytical high-performance liquid chromatography
(HPLC) stability studies were performed using a Symmetry® column (C18, 5 µm, 4.6×150 mm), a
Waters 2487 Dual Wavelength Absorbance detector, a Waters 1525 binary HPLC pump and a Waters
717plus Autosampler. Samples were detected at wavelength of 254 nm. All samples were analysed
using acetonitrile (80%): water (20%) as the mobile phase over 10 min and a flow rate of 1 mL/min.
Stock solutions are prepared by dissolving 5mg of compound in 10 mL of mobile phase. Phosphate
buffers at the desired pH values (4, 7.4, and 9) were prepared in accordance with the British
Pharmacopoeia monograph 2010. 30 µL of stock solution was diluted with 1 mL of appropriate buffer,
shaken and injected immediately. Samples were withdrawn and analysed at time intervals of t=0 min, 5
min, 30 min, 60 min, 90 min, 120 min and 21 hours.
Computational Procedure: For ligand preparation, all compounds were built using ACD/Chemsketch
v10 to generate SMILES. A single conformer from each string was generated using Corina v3.4 and
ensuring Omega v2.2.1 was subsequently employed to generate a maximum of 1000 conformations of
each compound. For the receptor preparation, the PDB entries 1SA0 were downloaded from the Protein
Data Bank (PDB). All waters were retained in both isoforms. Addition and optimisation of hydrogen
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positions for these waters was carried out using MOE 2007.09 ensuring all other atom positions
remained fixed. Using the reported X-ray structure of tubulin co-crystallised with a colchicine
derivative, DAMA-colchicine (PDB entry – 1SA0) 63, possible binding orientations ligands were probed
with the docking program FREDv2.2.3 (Openeye Scientific Software)64. Docking was carried out using
FREDv2.2.3 in conjunction with Chemgauss3, PLP Scoring function. 3-D ligand conformations were
enumerated using CORINAv3.4 (Molecular Networks GMBH)69 for ligands followed by generation of
multiple conformations using OMEGAv2.2.1 (Openeye Scientific Software)70. Each conformation was
subsequently docked and scored with Chemgauss3 PLP as outlined previously. 32 The top binding poses
were refined using the LigX procedure (MOE - Chemical Computing Group) 71 together with Postdock
analysis (SVL script; MOE) of the docked ligand poses.
X-ray crystallography
The X-ray crystallography data for crystal 32 was collected on a Rigaku Saturn 724 CCD
Diffractometer. A suitable crystal was selected and mounted on a glass fiber tip and placed on the
goniometer head in a 123K N2 gas stream. The data set was collected using Crystalclear-SM 1.4.0
software and 1680 diffraction images, of 0.5° per image, were recorded. Data integration, reduction and
correction for absorption and polarization effects were all performed using Crystalclear-SM 1.4.0
software. Space group determination, structure solution and refinement were obtained using
Crystalstructure ver. 3.8 and Bruker Shelxtl Ver. 6.14 software.72 Crystal Data for 32; C25H25NO5, MW
419.46, Orthorhombic, Space group Pbca; a = 18.876(9), b = 9.608(5), c = 23.662(12)A˚, α, β, γ = 90 o;
U = 4291(4) A˚; Z = 8; Dc = 1.298 Mg m-3; m = 0.090 mm-1; Range for data collection = 1.12–25.00;
Reflections collected 17904, Unique Reflections 3777 [Rint=0.1746]; Data/restraints/parameters
3777/0/284; Goodness-of-fit on F2 1.357; R indices (all data) = R1 = 0.1908, wR2 = 0.2609; Final R
indices [I > 2(I)] = R1 = 0.2366, wR2 = 0.2809. CCDC deposition No. 775568.
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Figure 1: Colchicine (1), Combretastatin A-4 (2a), related compounds 2b, 3a, 3b and Podophyllotoxin
(4)
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Figure 2: Ortep representation of the X-ray crystal structure of azetidinone 32 with 50% thermal
ellipsoids.
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Figure 3: Antiproliferative effect of β-lactam compounds 32 and 41 alongside 2a in MCF-7 human
breast cancer cells
MCF-7 cells were seeded at a density of 2.5 x 104 cells per well in 96 well plates. The plates were left
for 24 hours to allow the cells to adhere to the surface of the wells. A range of concentrations (0.01 nM50 µM) of the compound were added in triplicate and the cells left for another 72 hours. Control wells
contained the equivalent volume of the vehicle ethanol (1% v/v). An MTT assay was performed to
determine the level of anti-proliferation. The values represent the mean ± S.E.M (error values) for three
experiments performed in triplicate.
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Figure 4: Dose-response curve for β-lactams 35, 41 and 2a in murine mammary epithelial cells at
25,000 cells/ml
Mouse mammary epithelial cells were harvested from mid- to late- pregnant CD-1 mice and cultured.
The isolated mammary epithelial cells were seeded at two concentrations. After 24 hours, they were
treated with 2 µL volumes of test compound which had been pre-prepared as stock solutions in ethanol
to furnish the concentration range of study, 1 nM–100 µM, and re-incubated for a further 72 h. Control
wells contained the equivalent volume of the vehicle ethanol (1% v/v). The cytotoxicity was assessed
using alamar blue dye.
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Figure 5: Inhibition of tubulin polymerisation for compound 41
Effects of compound 41 on in vitro tubulin polymerisation. Purified bovine tubulin and GTP were
mixed in a 96-well plate. The reaction was started by warming the solution from 4 oC to 37oC. 2a
(10M) was used as a reference, while ethanol (1%v/v) was used as a vehicle control. The effect on
tubulin assembly was monitored in a Spectramax 340PC spectrophotometer at 340nm at 30 second
intervals for 60 minutes at 37 oC. Fold inhibition of tubulin polymerization was calculated using the
Vmax value for each reaction. The results represent the mean ± standard error of the mean for three
separate experiments.
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Figure 6a: Docked pose of β–lactam 32 in the colchicine binding site of tubulin
Docked pose of β–lactam 32 in the colchicine binding site of tubulin (PDB entry 1SA0). Significant
binding residues Cys 241 and Val 318 are indicated. Hydrogens are not shown for clarity. Coloured by
atom: Grey (carbon); red (oxygen); blue (nitrogen); yellow (sulfur). Residue numbers are those used by
Ravelli et al63.
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Figure 6b: Docked pose of 32 (coloured by atom) overlayed with N-deacetyl-N-(2-mercaptoacetyl)colchicine (DAMA-colchicine) (yellow) in the tubulin binding site (PDB entry 1SA0). Residues are not
shown for clarity.
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Figure 6c: 2D representation of the binding of β-lactam 32 in the colchicine-binding site of tubulin.
2-D rendering of ligand–protein interactions using LigX module of MOE used to create docked
structures of 32 in the colchicine-binding site of tubulin.
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Figure 7a: Proposed binding of β-lactam 41 in the colchicine binding site of tubulin (PDB entry 1SA0).
Docked pose of β-lactam 41 (green) in colchicine binding site of tubulin (PDB entry 1SA0). Hydrogens
are not shown for clarity. Significant binding residues Thr 179, Cys 241, Val 318 and Lys 254 are
indicated. Residue numbers are those used by Ravelli et al63.
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Figure 7b: Docked pose of β-lactam 41 in the colchicine binding site of tubulin (PDB entry 1SA0).
Docked pose of β-lactam 41 in colchicine binding site of tubulin (PDB entry 1SA0) with isolated
important residues. Hydrogens are not shown for clarity. Significant binding residues Cys 241, Val 318
and Lys 254 are indicated. Coloured by atom: Grey (carbon); red (oxygen); blue (nitrogen); yellow
(sulfur). Residue numbers are those used by Ravelli et al63.
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Figure 7c: 2D representation of the binding of β-lactam 41 in the colchicine-binding site of tubulin
2-D rendering of ligand–protein interactions using LigX module of MOE used to create docked
structures of 41 in the colchicine-binding site of tubulin.
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Figure 7d: Docked pose of 41 (coloured by atom) overlayed with N-deacetyl-N-(2-mercaptoacetyl)colchicine (DAMA-colchicine) (yellow) in the tubulin binding site (PDB entry 1SA0). Residues are not
shown for clarity.
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Scheme 1. Synthesis of imines 5a-fa

a

Reagents and conditions: (a) EtOH, reflux, 3 h
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Scheme 2: Synthesis of azetidinones 7 - 31, Routes I, II and IIIa,

a

Reagents and conditions: (a) SOCl2, CHCl3, reflux, 3 h; (b) (Route I) triethylamine, anhydrous CH2Cl2,

reflux, 3 h; (c) (Route II) triethylamine, anhydrous CH2Cl2, 20oC, 18h; (d) (Route III) triphosgene,
triethylamine, anhydrous CH2Cl2, reflux, 5 h; 20oC, stirred 18h.
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Scheme 3: Synthesis of azetidinones 32 - 34; Route IVa

a

Reagents and conditions: (a) Zinc, trimethylchlorosilane, benzene, microwave
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Scheme 4. Synthesis of azetidinones 35 - 38; Route Va

a

Reagents and conditions: TBAF, THF, 0˚C, 15 min
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Scheme 5. Synthesis of azetidinones 39 - 42; Route VI a
R2

R2
OCH3

OCH3

R1

R1
(a)

N

N
O

OCH3
H3CO

12:
28:
37:
31:

a

O

OCH3

OCH3
H3CO

R1=4-OCH2C6H5; R2=H
R1=3-OCH2C6H5; R2=H
R1=4-OCH2C6H5; R2=OH
R1=4-OCH2C6H5; R2=NO2

Reagents and conditions: (a) H2, Pd/C, EtOH:EtOAc (1:1).

45

OCH3

39: R1=4-OH; R2=H
40: R1=3-OH; R2=H
41: R1=4-OH; R2=OH
42: R1=4-OH; R2=NH2

Scheme 6: Synthesis of amino substituted azetidinones 43 – 45; Route VII a

a

Reagents and conditions: (a) Zn, CH3CO2H, 7 days
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Scheme 7. Synthesis of azetidinones 46 and 47; Route VIII a

a

Reagents and conditions: (a) H2, Pd/C, EtOH:EtOAc (1:1)
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Scheme 8. Synthesis of azetidinthione 48

a

Reagents and conditions: (a) Lawesson's reagent, toluene, reflux, 3h

48

Scheme 9: Azetidinone reduction and methanolysisa

a

Reagents and conditions: (a) LiAlH4, dry THF, reflux 3h (b) NaOCH3, MeOH, 20oC, 8 days.
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Table 1. Azetidinones with methoxy substitution at N-1, C-3 and C-4 aryl rings

Route

Compound
number

R1

R2

R3

R4

R5

R6

R7

R8

R9

for
synthesis

7

H

OCH3 H

H

H

H

OCH3 OCH3

OCH3

18

OCH3 OCH3 OCH3 H

H

H

H

OCH3

H

III

32

H

H

H

OCH3 OCH3 OCH3 H

OCH3

H

IV

33

H

H

H

H

OCH3

IV

OCH3 H
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OCH3 OCH3

I

Table 2. Azetidinones with C-3 aryl substitution

Route

Compound
R1

R2

R3

R4
synthesis

number
8

H

OCH3

H

H

I

9

H

H

OCH3

H

I

10

H

OCH3

OCH3

H

I

11

H

H

Cl

H

I

12

H

H

OCH2C6H5

H

I

15

H

H

NO2

H

II

19

OCH3

H

H

H

III

20

H

OCH3

OCH3

OCH3

III

21

H

H

SCH3

H

III

22

H

H

CH3

H

III

23

H

H

Br

H

III

24

H

H

F

H

III
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for

25

H

Cl

Cl

H

III

26

H

F

F

H

III

27

H

H

CF3

H

III

28

H

OCH2C6H5

H

H

III

32

H

H

H

H

IV

39

H

H

OH

H

II, VI

40

H

OH

H

H

III, VI

43

H

H

NH2

H

II, VII
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Table 3. Azetidinones with hydroxyl and amine-type substituents on C-3 and C-4 aryl rings and related
compounds

Compound
R1

R2

Route for Syntheiss

number
13

OSi(CH3)2C(CH3)3 F

I

14

NO2

H

I

16

NO2

NHC(O)OCH2C6H5

II

17

NO2

F

II

29

OSi(CH3)2C(CH3)3 OCH2C6H5

III

30

OSi(CH3)2C(CH3)3 NHC(O)OCH2C6H5

III

31

NO2

III

34

OSi(CH3)2C(CH3)3 H

35

OH

H

IV, V

36

OH

F

I, V

37

OH

OCH2C6H5

OCH2C6H5

IV

III, V
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38

OH

NHC(O)OCH2C6H5

41

OH

OH

III, VI, VI

42

NH2

OH

III, VI

44

NH2

H

I, VII

45

NH2

F

II, VII

46

OH

NH2

III, V, VIII

47

NH2

NH2

II, VIII

54

III, V

Table 4: Antiproliferative effects of azetidinones in MCF-7 human breast cancer cells
Compound

Antiproliferative

Compound

Antiproliferative

number

activity a,b

number

activity a,b

MCF-7 cells

MCF-7 cells

IC50 value (µM)

IC50 value (µM)

7

37.75 ± 23.35

27

1.6577 ± 0.4283

8

0.3263 ± 0.1565

32

0.0344 ± 0.0198

9

0.1820 ± 0.0262

33

43.12 ± 16.47

10

0.2228 ± 0.1585

35

0.0096 ± 0.0026

11

0.3052 ± 0.1380

36

0.0657 ± 0.0056

12

7.9857 ± 1.8590

39

0.0591 ± 0.0198

14

0.4663 ± 0.0361

40

0.0689 ± 0.0592

15

0.4856 ± 0.2815

41

0.0008 ± 0.0004

17

1.3642 ± 0.74

42

0.0395 ± 0.0216

18

43.13 ± 20.44

43

0.0508 ± 0.0194

19

0.6995 ± 0.1874

44

0.0653 ± 0.0111

20

7.1193 ± 3.9135

45

0.0553 ± 0.0087

21

0.4480 ± 0.2304

46

0.0045 ± 0.0032
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a

22

0.3152 ± 0.0714

47

0.0309 ± 0.0357

23

0.4196 ± 0.0817

48

0.72 ± 0.47

24

0.0423 ± 0.0420

49

24.5600 ± 2.6196

25

3.3607 ± 1.0377

50

>100

26

0.3139 ± 0.1792

2a

0.0052 ± 0.002

IC50 values are half maximal inhibitory concentrations required to block the growth stimulation of

MCF-7 or MDA-MB-231 cells. Values represent the mean ± S.E.M (error values x 10-6) for three
experiments performed in triplicate.
b

The IC50 values obtained for 2a in this assay are 0.0344 µM for MCF-7 and 0.043 µM for MDA-MB

231 and are in good agreement with the reported values for 2a using the MTT assay on human MCF-7
and MDA-MB 231 breast cancer cell lines, (see references 7, 73, 74).
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Table 5. Antiproliferative effects of selected -lactam compounds in MDA-MB-231 human breast
cancer cells

a

Compound

Antiproliferative

Compound

Antiproliferative

number

activity a,b

number

activity a,b

MDA-MB-231

MDA-MB-231

cells

cells

IC50 value (µM)

IC50 value (µM)

24

0.2284 ± 0.1755

41

0.1764 ± 0.1578

32

0.0782 ± 0.0348

42

1.6839 ± 1.9756

35

0.0288 ± 0.0199

43

0.2245 ± 0.1778

36

0.1072 ± 0.0558

44

0.4288 ± 0.0670

39

0.1577 ± 0.0352

45

0.0808 ± 0.0738

2a

0.043

IC50 values are half maximal inhibitory concentrations required to block the growth stimulation of

MCF-7 or MDA-MB-231 cells. Values represent the mean ± S.E.M (error values x 10-6) for three
experiments performed in triplicate.
b

The IC50 values obtained for 2a in this assay are 0.043 µM for MDA-MB 231 and is in good agreement

with the reported values for 2a using the MTT assay on MDA-MB 231 breast cancer cell lines, (see
references 7, 73, 74).
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Table 6: Inhibition of tubulin polymerization for compounds 32, 35, 41 and 2a
Fold-reduction in
Compound
Vmax at 10μM

a

2a

6.0 ± 1.4

32

6.1 ± 0.9

35

8.3 ± 2.6

41

11.76 ± 3.85

Effects of 2a, 32, 35 and 41 on in vitro tubulin polymerisation. Purified bovine tubulin and GTP were

mixed in a 96-well plate. The reaction was started by warming the solution from 4 oC to 37oC. 2a
(10M) was used as a reference, while ethanol (1%v/v) was used as a vehicle control. The effect on
tubulin assembly was monitored in a Spectramax 340PC spectrophotometer at 340nm at 30 second
intervals for 60 minutes at 37 oC. Fold inhibition of tubulin polymerization was calculated using the
Vmax value for each reaction. The results represent the mean ± standard error of the mean for three
separate experiments. Nd: not determined.
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